Medical supply chains are fragile in the best of times and COVID-19 will test their strength


The COVID-19 pandemic has introduced medical provide chains into the highlight. There has been a nationwide shortage of testing kits, and at the least one drug is already unavailable due to the outbreak, although it hasn’t been publicly named.

As operations engineers who concentrate on how these provide chains work, we all know that even in the most effective of instances, the U.S. drug provide chain is comparatively fragile. Shortages usually happen, and the COVID-19 pandemic has the potential to additional disrupt a system that sufferers depend upon, generally for all times or loss of life.

A snapshot of how medicine are made

Drugs may be divided into two broad classes: model title and generic.

Brand title medicine are these which are nonetheless patent-protected, like Chantix and Truvada. They’re usually very worthwhile for producers. This typically results in a dependable provide of such medicine, typically with some extent of redundancy – corporations might keep further capability or contract with a number of suppliers to forestall disruptions from inflicting shortages.

Patents, however, now not shield generic medicine like ibuprofen and azithromycin. The revenue margins for generic prescribed drugs are low, and the availability chains for generics with low demand are sometimes fragile. Almost 90% of the U.S. drug supply is generic.

A typical pharmaceutical provide chain begins with a producer of the energetic pharmaceutical elements, or API. API vegetation are sometimes abroad. China and India are major API producers, notably for generic medicine. The APIs are then shipped to vegetation the place they’re formulated into medicine for cargo to wholesalers, distributors, hospitals, pharmacies and sufferers.

Supply chains for generic medicine are sometimes lean. Typically every stage holds little inventory, starting from a number of weeks to some months. The energetic pharmaceutical ingredient could also be made by a single producer, and the completed type of the drug is sort of at all times made at a single manufacturing plant.

Federal regulatory protections require the API producer, the plant and the road on which the drug is manufactured all to be reviewed by the Food and Drug Administration. This is usually a prolonged course of.

This leanness signifies that an issue at any stage can disrupt the whole provide chain for months. The average drug shortage lasts 14 months, and a few have lasted for over three years. Unfortunately these will not be uncommon occasions and don’t solely occur when there are worldwide pandemics. Within the U.S., hundreds of drugs have been short since 2015 – together with most cancers therapies, antibiotics and central nervous system brokers.

Disruptions can take many kinds, and this leads again to the COVID-19 state of affairs. To curtail the unfold of the virus, many manufacturing plants in China were closed for weeks. In late February, the FDA introduced the first COVID-19-related drug shortage. Other such shortages might effectively happen.

Making certain the availability chain gained’t snap

The results of COVID-19 prolong past manufacturing. The pandemic might result in spikes in demand, which can in flip trigger shortages. This is what occurred for the check kits: Demand quickly elevated as soon as folks wanted to be examined. If demand surges for drugs as effectively – equivalent to hydroxychloroquine and chloroquine, that are being eyed as treatments for COVID-19 – there could also be shortages even when the availability is unaffected by plant shutdowns.

During the COVID-19 outbreaks, the general public can cut back shortages by taking motion to handle downstream results. “Flattening the curve” is about lowering demand spikes to assist well being programs handle the disaster with out changing into overloaded. By washing your fingers, bodily distancing and never hoarding, Americans may help to restrict the unfold of the virus and take a number of the stress off of hospitals.

Other methods embrace extending the available supply. For instance, the federal authorities or pharmaceutical corporations may prolong drug expiration dates if applicable, or scientists may develop strategies to check a number of folks utilizing the identical package.

At a broader scale, the U.S. ought to put sources into quickly ramping up manufacturing the place potential and protecting the availability chains as “connected” as they safely may be – for instance, persevering with to permit cargo to be shipped between continents even when passengers will not be.

In the long run, there are strategic steps manufacturers can take to reduce drug shortages. Decentralizing provide chains may assist counter upstream disruptions. Rather than producing a drug in a single plant, corporations may distribute manufacturing throughout a number of vegetation, ideally in several areas of the world. This may forestall a single downside from affecting the whole provide.

To improve provide and adaptableness, the federal authorities may allocate further sources to assist shorten the time it takes for businesses to evaluation whether or not manufacturing vegetation and suppliers are as much as security codes. Contracts to buy medicine may additionally incorporate incentives for corporations to take care of dependable provide chains. Many shortages are additionally brought on by manufacturing high quality points; investing in larger high quality manufacturing processes may cut back the frequency of disruptions.

Unfortunately, if provides will not be satisfactory, drugs may be rationed or sufferers might not obtain care. This, in impact, is at the least a part of what’s taking place with COVID-19 testing kits, the place demand is much higher than supply.

There are methods that pharmaceutical corporations and the federal government can and will pursue to reduce the results of the present disaster. However, till they put money into longer-term options, there’ll proceed to be medical shortages. These will not be straightforward selections in a time of excessive drug costs, however the COVID-19 pandemic ought to be a wake-up name to the vulnerabilities of medical provide chains.

[You need to understand the coronavirus pandemic, and we can help. Read our newsletter.]